Document is current
Any future updates will be listed below
-
Authors
Peplau, Emanuel
De Rose, Francesco
Eichinger, Andreas
Reder, Sybille
Mittelhäuser, Markus
Scafetta, Giorgia
Schwaiger, Markus
Weber, Wolfgang A.
Bartolazzi, Armando
D’Alessandria, Calogero
Skerra, Arne
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DA 1552/2-1)
Deutsche Forschungsgemeinschaft (SK 33/11-1)
Deutsche Forschungsgemeinschaft (CRC 824)
Technische Universität München
- License Information
-
More Information
Article History
Received: 7 December 2020
Accepted: 17 March 2021
First Online: 1 April 2021
Competing interests
: A.B. has an ownership of a patent related to the use of radiolabeled mAbs to galectin-3 for tumor imaging in vivo (patent no. 1388763, registered on February 20, 2008 Rome, Italy). A.S. is shareholder of XL-protein GmbH, the company that commercializes PASylation<sup>®</sup> technology. All other authors report no conflict of interest.
